KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Current Deferred Revenue (2017 - 2025)

Bionano Genomics' Current Deferred Revenue history spans 7 years, with the latest figure at $1.2 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 1.26% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, down 1.26%, while the annual FY2024 figure was $1.1 million, 44.06% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $1.2 million at Bionano Genomics, up from $1.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.2 million in Q3 2024 and bottomed at $301000.0 in Q1 2021.
  • The 5-year median for Current Deferred Revenue is $1.0 million (2025), against an average of $923368.4.
  • The largest annual shift saw Current Deferred Revenue surged 267.77% in 2022 before it fell 17.12% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $684000.0 in 2021, then increased by 27.34% to $871000.0 in 2022, then dropped by 10.1% to $783000.0 in 2023, then surged by 44.06% to $1.1 million in 2024, then rose by 4.61% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Current Deferred Revenue are $1.2 million (Q3 2025), $1.2 million (Q2 2025), and $1.0 million (Q1 2025).